HPHA Heidelberg Pharma AG

2.270USD2.070 EUR · XETRA+0.49%Mkt Cap: 106.22M USDP/E: —

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally. The company's lead product candid…

Key Statistics

Company
Market Cap106.22M USD
Enterprise Value77.16M USD
Revenue (TTM)10.22M USD
Gross Profit1.30M USD
Net Income (TTM)-46.37M USD
Revenue/Share0.22 USD
Last Price2.270 USD
Fiscal Year EndNov 2025
MR QuarterAug 2026
Employees33
CountryDE
SectorHealthcare
IndustryBiotechnology
ISINDE000A11QVV0
Valuation
P/E (Trailing)—
P/E (Forward)-4.12
PEG5.46
EV/EBITDA-2.16
EV/Revenue7.55
P/S10.39
P/B-4.65
EPS (TTM)-0.71 USD
EPS (Forward)-0.55 USD
52W Range
2.1727% of range3.663
52W High3.663 USD
52W Low2.172 USD
Profitability
Gross Margin81.31%
Oper. Margin-352.32%
EBITDA Margin0.00%
Profit Margin-2901.15%
ROE387.26%
ROA-110.87%
ROIC—
ROCE-174.72%
Growth
Revenue Growth3974.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-34.66M USD
CapEx (TTM)148.12K USD
FCF Margin-157.43%
FCF Yield-15.15%
Net Debt-21.43M USD
Net Debt/EBITDA0.60
Net Debt/FCF—
Balance Sheet
Debt/Equity-0.01
Current Ratio4.24
Quick Ratio2.96
Book Value/Sh-0.49 USD
Cash/Share0.50 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:4
Split DateJul 18, 2014
Analyst Consensus
Rating—
Target (Mean)7.403 USD
Upside (mean)+226.1%
Target Range6.032 USD – 8.774 USD
6.032+226.1% to mean8.774
# Analysts2
Ownership
Shares Out.46.78M
Float9.25M
Insiders79.00%
Institutions1.73%
Technical
SMA 502.492 (-8.9%)
SMA 2002.871 (-20.9%)
Beta0.78
S&P 52W Chg12.00%
Avg Vol (30d)3.61K
Avg Vol (10d)1.64K
Technical Indicators
RSI (14)42.6
MACD-0.0491
MACD Signal-0.0561
MACD Hist.+0.0071
BB Upper2.405 USD
BB Middle2.304 USD
BB Lower2.202 USD
BB Width8.81%
ATR (14)0.1042 USD
Vol Ratio (20d)0.03x

About Heidelberg Pharma (ETR: HPHA)

›

Heidelberg Pharma (ETR: HPHA) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 33 employees.

The shares were at 2.070 EUR on 19 November 2026, down 31.0% over 52 weeks. Its 52-week range is 1.980 EUR to 3.340 EUR: the price is 38.0% below the high and 4.5% above the low.

Its market capitalisation is 96.84M EUR.

Heidelberg Pharma reports return on equity of 387.3% and an operating margin of -352.3%.

It holds more cash than debt, a net cash position of 19.54M EUR. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 2 analysts cover the stock; their mean price target of 6.750 EUR is 226.1% above the current price.